Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of D064 and D701 Combination Therapy in Essential Hypertension
NCT05526703Phase 3Unknown
- Sponsor
- Chong Kun Dang Holdings
- Start
- Sep 2022
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of telmisartan, Levamlodipine in essential hypertension, sponsored by Chong Kun Dang Holdings. Status: unknown.
02
Drugs
telmisartanLevamlodipine
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT05526703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05526703.